Entrada Therapeutics Financials
| TRDA Stock | USD 18.80 0.75 4.16% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Debt Equity Ratio | 0.0397 | 0.0326 |
|
| |||||
| Current Ratio | 2.21 | 2.3286 |
|
|
The essential information of the day-to-day investment outlook for Entrada Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Entrada Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Entrada Therapeutics.
Net Income |
|
Entrada | Select Account or Indicator |
Understanding current and past Entrada Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Entrada Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Entrada Therapeutics' assets may result in an increase in income on the income statement.
Please note, the presentation of Entrada Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Entrada Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Entrada Therapeutics' management manipulating its earnings.
Entrada Therapeutics Stock Summary
Entrada Therapeutics competes with Molecular Partners, Pmv Pharmaceuticals, Monte Rosa, Vigil Neuroscience, and Third Harmonic. Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle therapeutics for the treatment of multiple neuromuscular diseases. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. Entrada Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 122 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US29384C1080 |
| CUSIP | 29384C108 |
| Location | Massachusetts; U.S.A |
| Business Address | One Design Center |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.entradatx.com |
| Phone | 857 520 9158 |
| Currency | USD - US Dollar |
Entrada Therapeutics Key Financial Ratios
| Return On Equity | 0.16 | ||||
| Profit Margin | 0.26 % | ||||
| Operating Margin | (1.11) % | ||||
| Price To Sales | 3.14 X | ||||
| Revenue | 129.01 M |
Entrada Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Entrada Therapeutics's current stock value. Our valuation model uses many indicators to compare Entrada Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Entrada Therapeutics competition to find correlations between indicators driving Entrada Therapeutics's intrinsic value. More Info.Entrada Therapeutics is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.42 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Entrada Therapeutics is roughly 2.36 . At present, Entrada Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Entrada Therapeutics' earnings, one of the primary drivers of an investment's value.Entrada Therapeutics Systematic Risk
Entrada Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Entrada Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Entrada Therapeutics correlated with the market. If Beta is less than 0 Entrada Therapeutics generally moves in the opposite direction as compared to the market. If Entrada Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Entrada Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Entrada Therapeutics is generally in the same direction as the market. If Beta > 1 Entrada Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Entrada Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Entrada Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Entrada Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Entrada Therapeutics November 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Entrada Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Entrada Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Entrada Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Entrada Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Entrada Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.09 | |||
| Information Ratio | 0.0254 | |||
| Maximum Drawdown | 18.81 | |||
| Value At Risk | (3.83) | |||
| Potential Upside | 6.14 |
Complementary Tools for Entrada Stock analysis
When running Entrada Therapeutics' price analysis, check to measure Entrada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entrada Therapeutics is operating at the current time. Most of Entrada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Entrada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entrada Therapeutics' price. Additionally, you may evaluate how the addition of Entrada Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |